Alpha Tau Medical Ltd. $DRTS Shares Acquired by Kovitz Investment Group Partners LLC

Key Points

• Kovitz Investment Group Partners LLC increased its stake in Alpha Tau Medical Ltd. by 601.4% during the first quarter, owning 226,320 shares valued at approximately $568,000.
• HC Wainwright reaffirmed a "buy" rating for the stock with a target price of $9.00, aligning with the consensus rating of "Buy" among analysts.
• Alpha Tau Medical reported a quarterly loss of ($0.13) earnings per share, slightly missing analyst expectations, with projections indicating an annual loss of ($0.45 EPS).

Kovitz Investment Group Partners LLC lifted its position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) by 601.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 226,320 shares of the company's stock after acquiring an additional 194,055 shares during the period. Kovitz Investment Group Partners LLC owned about 0.32% of Alpha Tau Medical worth $568,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. XTX Topco Ltd acquired a new stake in shares of Alpha Tau Medical during the 1st quarter valued at approximately $53,000. Renaissance Technologies LLC increased its position in Alpha Tau Medical by 188.7% in the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock worth $127,000 after buying an additional 26,800 shares during the period. Finally, Northern Trust Corp increased its position in Alpha Tau Medical by 112.6% in the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after buying an additional 25,770 shares during the period. 2.65% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $9.00 target price on shares of Alpha Tau Medical in a research report on Tuesday, April 29th. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, Alpha Tau Medical presently has an average rating of "Buy" and a consensus price target of $9.00.

Alpha Tau Medical Price Performance

Shares of NASDAQ DRTS opened at $3.06 on Thursday. Alpha Tau Medical Ltd. has a 1-year low of $2.11 and a 1-year high of $4.39. The company has a debt-to-equity ratio of 0.07, a current ratio of 10.52 and a quick ratio of 5.81. The business's fifty day moving average price is $3.10 and its two-hundred day moving average price is $2.90. The firm has a market capitalization of $259.55 million, a PE ratio of -6.38 and a beta of 0.99.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). On average, research analysts expect that Alpha Tau Medical Ltd. will post -0.45 EPS for the current year.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

Want to see what other hedge funds are holding DRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.